Cargando…

Failure of Oral Risedronate Therapy to Prevent Spontaneous Vertebral Fracture in a Patient Ceasing Denosumab: A Cautionary Case

Denosumab is a highly effective treatment for postmenopausal osteoporosis, significantly improving BMD and reducing risk of fracture. However, denosumab's effect is transient with the risk of a rebound increase in bone turnover following withdrawal of this potent RANKL inhibitor. This poses cha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davidoff, Dahlia F, Girgis, Christian M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574702/ https://www.ncbi.nlm.nih.gov/pubmed/33103026 http://dx.doi.org/10.1002/jbm4.10396

Ejemplares similares

Effect of risedronate on bone loss at discontinuation of denosumab
por: Laroche, Michel, et al.
Publicado: (2020)

Rebound Vertebral Fractures in a Patient With Lung Cancer After Oncology-Dose Denosumab Discontinuation: A Cautionary Tale
por: Tyan, Alexander, et al.
Publicado: (2019)

Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study
por: Tutaworn, Teerapat, et al.
Publicado: (2023)

Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: A case report
por: Kashii, Masafumi, et al.
Publicado: (2020)

Effect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment
por: Geusens, Piet, et al.
Publicado: (2022)

Multiple Spontaneous Vertebral Fractures in a Younger Post-menopausal Woman Upon Stopping Denosumab Therapy
por: Hu, Xun Yang, et al.
Publicado: (2023)

Raloxifene Has No Efficacy in Reducing the High Bone Turnover and the Risk of Spontaneous Vertebral Fractures after Denosumab Discontinuation
por: Gonzalez-Rodriguez, Elena, et al.
Publicado: (2018)

Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women
por: Osaki, M., et al.
Publicado: (2011)

Denosumab Reduces the Incidence of New Vertebral Fractures in Men With Prostate Cancer
por: Silver, David S.
Publicado: (2010)

Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab
por: Anastasilakis, Athanasios D., et al.
Publicado: (2023)

Effects of risedronate on fracture risk in postmenopausal women with osteopenia
por: Siris, E. S., et al.
Publicado: (2007)

A Review on the Role of Denosumab in Fracture Prevention
por: Pang, Kok-Lun, et al.
Publicado: (2020)

THU448 Multiple Non-traumatic Vertebral Fractures After Discontinuation Of Denosumab
por: Riahi, Shayan, et al.
Publicado: (2023)

Anti-fracture Efficacy of Monthly Risedronate Compared with That of Weekly Risedronate in Postmenopausal Korean Women with Osteoporosis: A Nationwide Cohort Study
por: Cho, Yong Ho, et al.
Publicado: (2020)

He Ceased to Be a Doctor
por: Gittins, Robert J.
Publicado: (1927)

He Ceased to Be a Doctor
por: Ogilvie, W. H.
Publicado: (1927)

When Ought Appeals to Cease?
Publicado: (1890)

Rebound-Associated Vertebral Fractures Two Months After a Missed Dose of Denosumab
por: Caseja, Ahl Jeffrey, et al.
Publicado: (2021)

Spontaneous Incomplete transverse subtrochanteric femoral fracture with cortical thickening possibly secondary to risedronate use: a case report
por: Alfahad, Anas, et al.
Publicado: (2012)

After a Fracture of the Limb the Nails of the Hand on the Same Side Cease Growing
Publicado: (1898)

Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA
por: Eisman, John A., et al.
Publicado: (2023)

Denosumab Versus Risedronate in Glucocorticoid‐Induced Osteoporosis: Final Results of a Twenty‐Four–Month Randomized, Double‐Blind, Double‐Dummy Trial
por: Saag, Kenneth G., et al.
Publicado: (2019)

Risedronate’s Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis
por: Gates, Brian J., et al.
Publicado: (2012)

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
por: Masud, Tahir, et al.
Publicado: (2009)

Periodontal Proteomics: Wonders Never Cease!
por: Grover, Harpreet Singh, et al.
Publicado: (2013)

Shall Nurses Cease to Be Laywomen?—IV
Publicado: (1891)

Shall Nurses Cease to Be Laywomen?—V
Publicado: (1891)

Shall Nurses Cease to Be Laywomen?—II
Publicado: (1891)

Shall Nurses Cease to Be Laywomen?—III
Publicado: (1891)

Effects of Risedronate on Osteoarthritis of the Knee
por: Iwamoto, Jun, et al.
Publicado: (2010)

Denosumab and atypical femoral fractures
por: Aspenberg, Per
Publicado: (2014)

SUN-LB66 Oral Risedronate Treatment in Children With Osteogenesis Imperfecta
por: Nguyen, Antoine T, et al.
Publicado: (2020)

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures
por: Austin, Matthew, et al.
Publicado: (2012)

Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases
por: Dupont, Jolan, et al.
Publicado: (2022)

The Indian Journal of Anaesthesia: The timeline never ceases
por: Bhaskar, S Bala
Publicado: (2016)

Shall Nurses Cease to Be Lay Women?—I
Publicado: (1891)

Will Gold Foil Cease to Be Chief of Filling-Materials?
Publicado: (1904)

When Does the Danger of Infection in Scarlatina Cease?
Publicado: (1882)

Once-monthly risedronate for postmenopausal osteoporosis
por: Casadei, Kristina, et al.
Publicado: (2010)

Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses
por: Cosman, Felicia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n1maf2b8jul8s092nak7aorb31